OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis

MLA

Romain Lannes, et al. “OAB-016: High Risk Subclones Detected at Relapse Are Present from Diagnosis in Small Subclones and Impact the Prognosis.” Clinical Lymphoma Myeloma and Leukemia, vol. 22, Aug. 2022, p. S10. EBSCOhost, https://doi.org/10.1016/s2152-2650(22)00289-0.

APA

Romain Lannes, Mehmet Samur, Aurore Perrot, Celine Mazzotti, Marion Divoux, Titouan Cazaubiel, Anaïs Schavgoulidze, Marie-Lorraine Chretien, Salomon Manier, Didier Adiko, Frederique Orsini-Piocelle, François Lifermann, Sabine Brechignac, Lauris Gastaud, Didier Bouscary, Margaret Macro, Alice Cleynen, Mohamad Mohty, Nikhil Munshi, … Hervé Avet-Loiseau. (2022). OAB-016: High risk subclones detected at relapse are present from diagnosis in small subclones and impact the prognosis. Clinical Lymphoma Myeloma and Leukemia, 22, S10. https://doi.org/10.1016/s2152-2650(22)00289-0

Chicago

Romain Lannes, Mehmet Samur, Aurore Perrot, Celine Mazzotti, Marion Divoux, Titouan Cazaubiel, Anaïs Schavgoulidze, et al. 2022. “OAB-016: High Risk Subclones Detected at Relapse Are Present from Diagnosis in Small Subclones and Impact the Prognosis.” Clinical Lymphoma Myeloma and Leukemia 22 (August): S10. doi:10.1016/s2152-2650(22)00289-0.